At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
gadobenate dimeglumine (MultiHance)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Oct 4, 2007·Updated Sep 26, 2017
In Brief
A clinical study evaluating gadobenate dimeglumine (MultiHance) for Hepatocellular Carcinoma. Completed, enrolled 45 participants across 1 site.
Detailed Summary
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
CollaboratorsBracco Diagnostics, Inc
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedOct 2007
Primary CompletionMar 2013
Study CompletionDec 2013
TodayJul 2026
First PostedOct 4, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 18.7 years ago
Interventions
gadobenate dimeglumine (MultiHance)drug
The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.